Myocyte-specific enhancer factor 2 (MEF2)

Myocyte-specific enhancer factor 2 (MEF2) is a family of transcription factors, including isoforms MEF2A, -B, -C, and -D, that serve as critical regulators of cellular differentiation and maintenance in muscle and neural tissues [1, 3]. These proteins belong to the MADS-box family and function as molecular switches that integrate signals from various pathways, such as calcium/calmodulin-dependent signaling and mitogen-activated protein kinase (MAPK) cascades, to control gene expression [2, 5]. MEF2 activity is primarily modulated through interactions with co-activators like p300 and co-repressors such as Class IIa histone deacetylases (HDACs), which sequester MEF2 in an inactive state until signaling-induced phosphorylation triggers their release [5, 13]. Dysregulation of MEF2 is heavily implicated in the pathogenesis of cardiac hypertrophy, heart failure, and neurodegenerative disorders like Parkinson's and Alzheimer's disease [2, 8, 11]. In oncology, MEF2 members can act as either oncogenes or tumor suppressors depending on the tissue context, often promoting epithelial-mesenchymal transition (EMT) and resistance to chemotherapy [1, 6]. Therapeutic strategies targeting MEF2 currently focus on epigenetic modulation via HDAC inhibitors or the inhibition of upstream kinases to restore physiological transcriptional programs [1, 2].

Other names

MEF2 familyMADS-box transcription factorMyocyte enhancer factor 2AMyocyte enhancer factor 2BMyocyte enhancer factor 2CMyocyte enhancer factor 2D

Transcriptional regulation through the recruitment of co-activators (e.g., p300/CBP) or co-repressors (e.g., Class IIa HDACs) to specific DNA sequences (A/T-rich elements) in the promoters of target genes [1, 5, 13].